PREEMS: Rheumatoid Purpura in Children: a Multicenter Observational Study of Pediatric Emergency Department Management and Follow-up by Primary Care Physicians

Sponsor
Groupe Hospitalier de la Region de Mulhouse et Sud Alsace (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05737056
Collaborator
(none)
45
6

Study Details

Study Description

Brief Summary

The main objective of this study is to describe the management of children with rheumatoid purpura from admission to the pediatric emergency room to follow-up by primary care physicians after hospital discharge.

Condition or Disease Intervention/Treatment Phase
  • Other: Management of rheumatoid purpura

Detailed Description

Secondary objectives The secondary objective is to evaluate the knowledge and current practices of general practitioners on the pathology and the possible obstacles to a monitoring and a follow-up by general practitioners.

Conduct of research Children who have been diagnosed with rheumatoid purpura within the last two years at the three participating sites will be enrolled in the study if the legal guardians do not object to it. Patients will be identified through the Medical Information Department of each hospital.

Legal guardians will be contacted - by mail first, then by phone - for two purposes :
  • allow the collection of data at the time of diagnosis at the pediatric emergency from medical records

  • and give information on how the disease was monitored and followed up by general practitioners up to two years after diagnosis

Study Design

Study Type:
Observational
Anticipated Enrollment :
45 participants
Observational Model:
Cohort
Time Perspective:
Retrospective
Official Title:
Rheumatoid Purpura in Children: a Multicenter Observational Study of Pediatric Emergency Department Management and Follow-up by Primary Care Physicians
Anticipated Study Start Date :
Mar 1, 2023
Anticipated Primary Completion Date :
Sep 1, 2023
Anticipated Study Completion Date :
Sep 1, 2023

Arms and Interventions

Arm Intervention/Treatment
Children diagnosed with rheumatoid purpura at the pediatric emergency department

Children diagnosed with rheumatoid purpura from admission to the pediatric emergency department up to two years of follow-up by general practitioners after hospital discharge.

Other: Management of rheumatoid purpura
Collection of data related to the management of pediatric emergencies (diagnostic method, additional tests, proposed treatment, number of hospitalizations, follow-up after hospital discharge)

Outcome Measures

Primary Outcome Measures

  1. Compliance with the recommendations for the management of rheumatoid purpura [Up to two years after hospital discharge]

Secondary Outcome Measures

  1. Knowledge assessment questionnaire regarding rheumatoid purpura [At the begining of the study]

    Evaluation of the knowledge and current practices of general practitioners regarding rheumatoid purpura and identification of the possible obstacles to management and follow-up in primary care, using an online survey

Eligibility Criteria

Criteria

Ages Eligible for Study:
0 Years to 18 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Minor patient diagnosed with rheumatoid purpura during a visit to the pediatric emergencies of Mulhouse, Colmar and Strasbourg

  • No objection to the study from the two holders of parental authority

Exclusion Criteria:
  • Patient followed in the context of a genetic or malformative pathology, an immune deficiency, or a cancer

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Groupe Hospitalier de la Region de Mulhouse et Sud Alsace

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Groupe Hospitalier de la Region de Mulhouse et Sud Alsace
ClinicalTrials.gov Identifier:
NCT05737056
Other Study ID Numbers:
  • GHRMSA 1278
First Posted:
Feb 21, 2023
Last Update Posted:
Feb 21, 2023
Last Verified:
Feb 1, 2023
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Feb 21, 2023